Needham & Company LLC Reaffirms Buy Rating for LivaNova (NASDAQ:LIVN)

Needham & Company LLC restated their buy rating on shares of LivaNova (NASDAQ:LIVN) in a research report report published on Tuesday,Benzinga reports. They currently have a $75.00 price objective on the stock.

Several other analysts also recently issued reports on the company. Robert W. Baird boosted their price target on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. The Goldman Sachs Group began coverage on LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 price target for the company. Mizuho reduced their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. Finally, StockNews.com downgraded LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 23rd. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, LivaNova has an average rating of “Buy” and an average target price of $69.17.

LivaNova Stock Up 2.0 %

LIVN stock opened at $50.53 on Tuesday. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $2.74 billion, a PE ratio of 120.31 and a beta of 1.01. LivaNova has a 1-year low of $43.15 and a 1-year high of $64.47. The business’s 50 day simple moving average is $49.05 and its 200 day simple moving average is $49.97.

Insider Buying and Selling

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the transaction, the director now owns 7,522 shares of the company’s stock, valued at $383,546.78. This represents a 14.25 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.27% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On LivaNova

A number of institutional investors and hedge funds have recently bought and sold shares of LIVN. Point72 Asset Management L.P. increased its holdings in LivaNova by 62.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock worth $109,914,000 after purchasing an additional 806,374 shares in the last quarter. Point72 DIFC Ltd increased its holdings in LivaNova by 75,799.6% in the 3rd quarter. Point72 DIFC Ltd now owns 181,400 shares of the company’s stock worth $9,531,000 after purchasing an additional 181,161 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in LivaNova by 286.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 207,248 shares of the company’s stock worth $10,889,000 after purchasing an additional 153,611 shares in the last quarter. Victory Capital Management Inc. increased its holdings in LivaNova by 16.6% in the 3rd quarter. Victory Capital Management Inc. now owns 935,102 shares of the company’s stock worth $49,130,000 after purchasing an additional 133,401 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in LivaNova by 17.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company’s stock worth $32,678,000 after purchasing an additional 93,311 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.